Concord Biotech Limited, an India-based R&D-driven biopharma company specializing in fermentation-based APIs for immunosuppressants and oncology, reported a decline in financial performance for Q2FY26.
Financial Highlights:
- Revenues declined 20.32% year-on-year to ₹247 crore from ₹310 crore.
- Total expenses decreased 6.35% to ₹177 crore from ₹189 crore.
- Consolidated net profit dropped 34.38% to ₹63 crore from ₹96 crore.
- Earnings per share fell 33.55% to ₹6.08 from ₹9.15.
The profit decline was primarily due to lower revenues despite cost reductions. The company is focusing on strengthening its product pipeline and operational efficiencies.
Outlook:
Concord Biotech aims to enhance R&D, expand its product portfolio, and improve manufacturing capabilities to drive future growth. It is well-positioned to benefit from growing demand in immunosuppressants and oncology segments.
Explore the company’s past earnings and latest concall transcripts, click here to visit the AlphaStreet India News Channel.
Most Popular
Cochin Shipyard Ltd (COCHINSHIP) Q4 FY22 Earnings Concall Transcript
Cochin Shipyard Limited (NSE:COCHINSHIP) Q4 FY22 Earnings Concall dated May. 26, 2022 Corporate Participants: Madhu S Nair -- Chairman & Managing Director Jose V J -- Director Finance Analysts: Vastupal Shah
All you need to know about Antony Waste Handling Cell in one article
Can you guess the name of the company that was listed during the IPO frenzy in 2020 and is the second largest player in the Indian municipal waste management industry?
Demystifying the Leading Non-Ferrous Recycling Company of India
“Hey, how is the market doing today?” “Oh!, its falling tremendously since morning” I am sure news like these might be a common topic of discussion for you nowadays. Interestingly,